June 4th Lead Plaintiff Deadline Approaching in Class Action Against Checkpoint Therapeutics, Inc. – Contact Robbins LLP Today Robbins LLP is Investigating the Allegations that Checkpoint Therapeutics, Inc. Overstated the Prospects of its Lead Product Candidate, Cosibelimab

Robbins LLP Reminds Stockholders of CKPT to Contact the Law Firm for Information About the Checkpoint Therapeutics, Inc. Class Action Lawsuit Robbins LLP is Investigating the Allegations that Checkpoint Therapeutics, Inc. Overstated the Prospects of its Lead Product Candidate, Cosibelimab

CKPT Class Action Alert: Robbins LLP Reminds Stockholders of Checkpoint Therapeutics, Inc. Class Action Robbins LLP is Investigating the Allegations that Checkpoint Therapeutics, Inc. Overstated the Prospects of its Lead Product Candidate, Cosibelimab

Investor Notice: Robbins LLP Informs Investors of Class Action Filed Against Checkpoint Therapeutics, Inc. (CKPT) Robbins LLP is Investigating the Allegations that Checkpoint Therapeutics, Inc. Overstated the Prospects of its Lead Product Candidate, Cosibelimab